LQDA
Liquidia CorporationNASDAQHealthcare$37.68+0.56%ClosedMarket Cap: $3.32B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
73.29
P/S
20.95
EV/EBITDA
-74.06
DCF Value
$-98.68
FCF Yield
-1.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.2%
Operating Margin
-32.5%
Net Margin
-43.5%
ROE
-209.3%
ROA
-21.0%
ROIC
-20.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $92.0M | $14.6M | $0.15 |
| FY 2025 | $158.3M | $-68.9M | $-0.80 |
| Q3 2025 | $54.3M | $-3.5M | $-0.04 |
| Q2 2025 | $8.8M | $-41.6M | $-0.49 |
Trading Activity
Insider Trades
View AllBloch Stephen Mdirector
SellMon Mar 30
Bloch Stephen Mdirector
SellMon Mar 30
Bloch Stephen Mdirector
SellMon Mar 30
Bloch Stephen Mdirector
SellMon Mar 30
Moomaw Scottofficer: Chief Commercial Officer
SellWed Mar 25
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.46
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.